Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2006-01-13
2009-10-27
Vogel, Nancy (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
C435S325000, C435S455000
Reexamination Certificate
active
07608431
ABSTRACT:
The invention provides processes for recombinant production of erythropoietin (EPO) in a human embryonic retina cell that expresses at least an adenoviral E1A protein, wherein said EPO is produced at high concentrations and wherein said EPO as produced has a high average sialic acid content per EPO molecule.
REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4835260 (1989-05-01), Shoemaker
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5192539 (1993-03-01), Van Der Marel et al.
patent: 5441868 (1995-08-01), Lin
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5494790 (1996-02-01), Sasaki et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5789247 (1998-08-01), Ballay et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5835382 (1998-11-01), Wilson et al.
patent: 5856292 (1999-01-01), Thomas et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6395519 (2002-05-01), Fallaux et al.
patent: 6413746 (2002-07-01), Field
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6506598 (2003-01-01), Andersen et al.
patent: 6558948 (2003-05-01), Kochanek et al.
patent: 6653101 (2003-11-01), Cockett et al.
patent: 6855544 (2005-02-01), Hateboer et al.
patent: 6878549 (2005-04-01), Vogels et al.
patent: 7132280 (2006-11-01), Bout et al.
patent: 2002/0116723 (2002-08-01), Grigliatti et al.
patent: 2003/0087437 (2003-05-01), Asada et al.
patent: 2003/0092160 (2003-05-01), Bout et al.
patent: 2005/0164386 (2005-07-01), Uytdehaag et al.
patent: 2005/0181359 (2005-08-01), Optelten et al.
patent: 2005/0288220 (2005-12-01), Burg et al.
patent: 0 185 573 (1986-06-01), None
patent: 0 411 678 (1991-02-01), None
patent: 0 833 934 (1998-04-01), None
patent: 1 108 787 (2001-06-01), None
patent: WO 93/03163 (1993-02-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 95/29994 (1995-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 97/18318 (1997-05-01), None
patent: WO 98/18926 (1998-05-01), None
patent: WO 98/39411 (1998-09-01), None
patent: WO 98/44141 (1998-10-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/24068 (1999-05-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/05945 (2001-01-01), None
patent: WO 01/38362 (2001-05-01), None
patent: WO 02/18948 (2002-03-01), None
patent: WO 02/053580 (2002-07-01), None
patent: WO 03/003810 (2003-05-01), None
patent: WO 03/048197 (2003-06-01), None
patent: WO 03/048348 (2003-06-01), None
patent: WO 03/051927 (2003-06-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004058944 (2004-07-01), None
patent: WO 2004/099396 (2004-11-01), None
patent: WO 2004099396 (2004-11-01), None
Kurokawa et al Biotech. Bioeng. 1994. vol. 44, pp. 95-103.
www.peptideguide.com.
#Alkhatib et al., “Expression of Bicistronic Measles Virus P/C mRNA by Using Hybrid Adenovirus: Levels of C Protein Synthesized in Vivo Are Unaffected by the Presence or Absence of the Upstream P Initiator Codon,” Journal of Virology, Nov. 1988, pp. 4059-4068, vol. 62, No. 11.
#Alkhatib et al., “High-Level Eurcaryotic In Vivo Expression of Biologically Active Measles Virus Hemagglutinin by Using an Adenovirus Type 5 Helper-Free Vector System,” Journal of Virology, Aug. 1988, pp. 2718-2727, vol. 62, No. 8.
#Berg et al., High-Level Expression of Secreted Proteins from Cells Adapted to Serum-Free Suspension Culture, Research Report, BioTechniques 1993, pp. 972-978, vol. 14, No. 6.
#Bout et al., “Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors,” Cancer Gene Therapy, 1996, pp. S24, vol. 3, No. 6.
#Bout et al., “PER.C6 as production platform for human monoclonal antibodies,” Human Antibodies, Oct. 8, 2003, pp. 30, vol. 12, No. 1-2.
#Bout et al., “Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6,” Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.
#Boutl et al., A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, vol. 4, No. 6.
#Brown et al., “Evaluation of Cell Line 293 for Virus isolation in Routine Viral Diagnosis,” Journal of Clinical Microbiology, Apr. 1986, pp. 704-708, vol. 23, No. 4.
#Bukreyev et al., “Recombinant Respiratory Syncytial Virus from Which the Entire SH Gene Has Been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,” Journal of Virology, Dec. 1997, pp. 8973-8982, vol. 71, No. 12.
#Caravokyri et al., “Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5,” Journal of Virology, Nov. 1995, pp. 6627-6633, vol. 69, No. 11.
#Carroll et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-179, vol. 3, No. 2.
#Certificate of deposit of the PER.C6 cell line (ECACC deposit under No. 96022940).
#Ciccarone at al., “Lipofectamine 2000 Reagent for Transfection of Eukaryotic Cells,” Focus, 1999, pp. 54-55, vol. 21, No. 2.
#Cote et al., Serum-Free Production of Recombinant Proteins and Adenoviral Vectors by 293SF-3F6 Cells, Biotechnology and Bioengineering, Sep. 5, 1998, pp. 567-575, vol. 59, No. 5.
#Cronan, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, Jun. 25, 1990, pp. 10327-10333, vol. 265, No. 18.
#DuBridge et al., “Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System,” Molecular and Cellular Biology, Jan. 1987, pp. 397-387, vol. 7, No. 1.
#Endo et al., Growth of Influenza A Virus in Primary, Differentiated Epithelial Cells Derived from Adenoids, Journal of Virology, Mar. 1996, pp. 2055-2058, vol. 70, No. 3.
#Fallaux et al, “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Human Gene Therapy, Sep. 1, 1998, vol. 9, No. 1, pp. 1909-1917. Abstract.
#Fallaux et al., Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors, Human Gene Therapy, Jan. 20, 1996, pp. 215-222, vol. 7.
#Gallimore et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, vol. 6.
#Garnier et al., Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells, Cytotechnology, 1994, pp. 145-155, vol. 15.
#GenBank Accession No. X02996.1, 1993, “Adenovirus type 5 left 32% of the genome.”
#Ghosh-Choudhury et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-1739, vol. 6, No. 6.
#GIBCO cell culture, A Guide to Serum-Free Cell Culture, www.invitrogen.com.
#Grabenhorst et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GlcNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1-4)GlcNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 718-725, vol. 232, No. 3, Berlin, Germany.
#Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol., 1997, pp. 59-72, vol. 36.
#Graham et al., “Growth of 293 cells in suspension culture,” J Gen Virol, Mar. 1987, pp. 937-940, vol. 68.
#Graham, Cell Lines, Promochem (visited Apr. 10, 2005) <http://www.lgcpromochem-atcc.com/SearchCatalogs/longview.cfm?view=ce,1146
Crucell Holland B.V.
Joike Michele K.
TraskBritt
Vogel Nancy
LandOfFree
Fed-batch process for production of erythropoietin in human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fed-batch process for production of erythropoietin in human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fed-batch process for production of erythropoietin in human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4076570